logo
Ensuring Financial Data Security In The Quantum Era

Ensuring Financial Data Security In The Quantum Era

Forbes22-05-2025
Financial market organizations are used to the idea of speculation. Buying undervalued assets to realize value from them at a later point is a well-established strategy. But – on the other side of a very dark mirror – another kind of speculation is stalking even well-established financial players.
Bad actors are already exploring the next horizon of cyber-attacks with the goal of harvesting encrypted data. Today, the encryption is safe and the data is useless to the thieves. But they speculate that, armed at some point in the future with a 'cryptographically-relevant quantum computer (CRQC) – a quantum computer equipped with the right software – they will be able to break the encryption and gain access to the data, with devastating consequences. This point in time is often referred to as Q-Day.
While quantum threats will target industries ranging from power utilities to transportation providers, we believe the financial sector will be near the top of the list of targets for threat actors. The potential gains from stealing money or creating mayhem in the markets will be too appealing to pass up.
The good news is that Q-Day is not yet upon us, and there are actions that banking, financial services and insurance (BFSI) companies can take now to prepare for the quantum security threats of the future. It is possible that the quantum era could simply look like business as we know it, with full continuity of operations and management of risks.
For BFSI companies, data security is a significant challenge that gets more difficult with every passing day, even without the looming threat of a CRQC. Today's financial institutions are using more connected devices than ever. More devices means more potential backdoors or other vulnerabilities that can be exploited. Additionally, a recent report by the US Department of the Treasury found financial institutions are seeing an increase in more sophisticated, AI-powered phishing and social engineering attacks.
Where sensitive financial data is stored and managed, and how it is transported for transactions, is also cause for concern. Years ago, financial institutions would have hosted their data workloads in their own on-premises data centers. Now, in a highly digitalized financial world, workloads are often distributed across multiple public and private cloud networks, meaning financial institutions have less visibility and control over the security of their data once it leaves their premises. While financial institutions can (and do) encrypt data to protect it as it travels between clouds, they must trust that their service agreements will hold true and cloud-based data repositories are fully secured to their specifications.
Adding to this challenge are the increasingly stringent (but fragmented) regulatory requirements around data sovereignty and privacy, especially for enterprises with operations in multiple countries. It's not easy to determine the best way to comply with DORA, NIS2, OSFI B-13, CPS 230, NIST CSF 2.0 and the many other standards that are all very similar but different in their own ways. Even if an enterprise's headquarters isn't subject to a specific standard, that doesn't necessarily mean its satellite operations, or its globally distributed customer base aren't affected.
That said, in today's rapidly evolving geopolitical climate, many BFSI companies want to avoid having their data travel through certain countries, preferring to keep everything — including the people and systems managing their data and devices — within their own jurisdictions. That's not always easy to do, especially with the industry's high levels of AI usage.
The financial services sector is among the most mature when it comes to AI adoption, using the technology for a broad range of applications. For example, AI is being used for fraud detection to identify anomalies and suspicious activities in financial transactions. According to Mastercard, AI software can boost a bank's fraud detection rates by an average of 20% — and in some instances, by up to 300%. Additionally, AI-powered transaction monitoring can help cut down 'false positives' (i.e., when a legitimate transaction is mistakenly flagged as a fraudulent one) by more than 85%. But given that most banks don't have the infrastructure in place to build and train their own AI models, where is that AI analysis actually happening? How much sensitive customer data is now being stored and processed off-premises in an AI cloud? How secure are the AI models themselves?
Questions like these are enough to keep CTOs, CISOs and risk management teams up at night right now. When AI and quantum computing eventually converge, we can assume BFSI companies will need to adapt even faster to an ever-evolving threat landscape.
To protect their data in the AI and quantum era, BFSI companies can take the following actions, starting today:
With Q-Day looming, the worst thing banks and other financial institutions can do is nothing. Companies can and must take action now to protect their financial applications, systems and digitalization investments.
Of course, conducting infrastructure assessments and upgrading networks takes time as well as the right expertise and skills. But even though the word 'quantum' on its own can feel like a major technology leap, companies don't need to have quantum engineers on staff to set up the systems required to defend against future quantum cybersecurity threats. They also don't need to do this alone. Experienced IT network partners who have successfully deployed quantum-safe networks for financial institutions have the expertise to guide them through the process of architecting their networking and security technology evolution, every step of the way. The result? A solid, secure foundation to protect BFSI companies from today's threats and mitigate the risk of the threats still to come, so these institutions can thrive in the era of quantum computing and AI.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

World's Most Powerful Wi-Fi Hotspot, Sonim MegaConnect, Delivers Superior Connectivity for Public Safety on FirstNet
World's Most Powerful Wi-Fi Hotspot, Sonim MegaConnect, Delivers Superior Connectivity for Public Safety on FirstNet

Yahoo

time4 minutes ago

  • Yahoo

World's Most Powerful Wi-Fi Hotspot, Sonim MegaConnect, Delivers Superior Connectivity for Public Safety on FirstNet

Able to fit in your hand, the ruggedized Sonim MegaConnect(TM) gives public safety more power, faster speeds, and more flexibility than ever before. Key Takeaways: The ultra-portable and ruggedized MegaConnect - the smallest and most affordable high-powered user equipment (HPUE) on the market - is built to withstand the demanding conditions first responders face The new Wi-Fi hotspot transmits 6x the power and is up to 2x faster than standard devices, providing better coverage in rural areas and dense urban buildings Next-generation AirJet solid-state active cooling from Frore Systems unlocks full HPUE performance for the first time in a compact palm sized package. And coming later this year, a new, portable dock from Parsec will give the MegaConnect more than double the reach. San Diego, California and Dallas, Texas--(Newsfile Corp. - July 16, 2025) - With the new Sonim MegaConnect, the industry's first ultra-portable 5G1 HPUE mobile hotspot, public safety on FirstNet®, Built with AT&T - America's only 5G network built with and for first responders - have a new way to stay connected on-the-go. (C)2025 Sonim Technologies, Inc. All rights reserved. Sonim MegaConnect -- the industry's first HPUE mobile hotspot. To view an enhanced version of this graphic, please visit: Sonim Technologies (NASDAQ: SONM) designed the new MegaConnect to address the unique connectivity needs of mission-critical users, as a part of the FirstNet MegaRange™ HPUE portfolio. Giving public safety a mobile connectivity solution that delivers superior coverage to areas beyond the reach of traditional cellular networks, it has 6x the transmission power of standard hotspots because it runs on Band 14—nationwide, high-quality spectrum set aside by the government specifically for FirstNet— and additional connectivity via AT&T 5G and LTE commercial spectrum bands. That means MegaConnect provides expanded coverage in remote areas and better penetrates through signal-blocking materials like glass, concrete, and metal. One-third the size of other HPUE devices available today and easily able to fit in the palm of your hand, the MegaConnect allows first responders to stay connected - wherever the mission takes them. Currently, the most affordable HPUE on the market, it gives first responders the dependable, high-speed communications they need for now just $99. "As a brand trusted by the world's most demanding users, reliability and ruggedness are at the heart of everything we build at Sonim," said Chuck Becher, General Manager of North America and Chief Commercial Officer of Sonim Technologies. "The Sonim MegaConnect 5G Mobile Hotspot pushes the boundaries of mobile connectivity by blending high-power connectivity and true mobility into one device. It's the only HPUE communication tool that can be battery-operated in a compact form factor that mission-critical teams can trust to keep them connected, no matter where duty calls." Unique, Innovative Capabilities Delivering up to twice the upload speed of standard devices, the MegaConnect empowers first responders to send critical data faster than ever before. From streaming live video feeds and high-resolution drone footage to setting up mobile command centers, public safety can have the lightning-fast upload speeds they need to send mission-critical data in the field. The MegaConnect is designed for durability and portability and built to ensure ease of deployment in any situation—whether during a natural disaster or inside an underground garage. Able to be easily carried or docked, the MegaConnect allows responders to easily take the mobile hotspot with them as an emergency evolves, providing connectivity for various devices when they're needed the most. Plus, coming later this year, public safety will be able to double the MegaConnect's 6x power boost to up to 12x with the new Parsec MegaReach™ Dock. With integrated high-gain antennas and advanced thermal management, this ultra-portable dock ensures first responders and field teams can carry next-generation connectivity wherever duty calls—without compromise. "FirstNet is built with and for first responders, and we have a mission like no other carrier to drive innovative public safety-centric connectivity solutions that meet their unique needs," said Matt Walsh, AVP, FirstNet and NextGen 9-1-1 Products, AT&T. "Highly-portable and incredibly powerful, the MegaConnect is a game changer for first responders, whether they are handling an everyday emergency or a large-scale disaster." Innovative, next-generation cooling capabilities inside the MegaConnect remove the heat created by the HPUE device, unlocking its full performance and making this mobile hotspot ideal for first responders on-the-go. Until recently, the heat generated by HPUEs made true portability an impossibility. Now equipped with Airjet, a breakthrough solid-state active cooling chip from Frore Systems, the MegaConnect stays cool while keeping public safety connected - especially ideal for users, like first responders, who need communication anywhere anytime. And reliable, all-day battery performance, gives first responders uninterrupted connectivity for extended mission-critical responses. Beyond first responders and the public safety community on FirstNet, this solution is also available to utilities, financial institutions, remote data centers, transportation-related businesses, retail, and other enterprises with remote-monitored infrastructure on the AT&T commercial network. When not in use by public safety on FirstNet, these enterprise entities can take advantage of the unique benefits of Band 14, including 6x the transmission power. Availability Beginning today, the Sonim MegaConnect is available exclusively through AT&T and FirstNet channels at an MSRP of $499, with a promotional price of $99* for a limited time. Learn more at 1 FirstNet 5G is not available everywhere. See for coverage details. *Only in select channels. Available only to qualified FirstNet Agency customers. Requires new line and eligible service (minimum $34/mo.). Up to $50 activation fee may apply. Early termination fee (up to $750), other fees, taxes, charges and restrictions apply. Subject to change. Get $400 off eligible MegaRange devices with a 2-year service commitment. Offers and requirements subject to change at any time and without notice. ©2025 AT&T Intellectual Property. FirstNet and the FirstNet logo are registered trademarks and service marks of the First Responder Network Authority. All other marks are the property of their respective owners. Sonim and Sonim MegaConnect are registered trademarks and trademarks of Sonim Technologies, Inc. About Sonim TechnologiesSonim Technologies (NASDAQ: SONM) is a leading U.S. provider of rugged mobile solutions, including phones, wireless internet data devices, accessories and software designed to provide extra protection for users that demand more durability in their work and everyday lives. Trusted by first responders, government, and Fortune 500 customers since 1999, we currently sell our ruggedized mobility solutions through tier one wireless carriers and distributors in North America, EMEA, and Australia/New Zealand. Sonim devices and accessories connect users with voice, data, workflow and lifestyle applications that enhance the user experience while providing an extra level of protection. For more information, visit Media contact:Anette 619-993-3058 Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements relate to, among other things, the timeline of new products. These forward-looking statements are based on Sonim's current expectations, estimates and projections about its business and industry, management's beliefs and certain assumptions made by Sonim, all of which are subject to change. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "achieve," "aim," "ambitions," "anticipate," "believe," "committed," "continue," "could," "designed," "estimate," "expect," "forecast," "future," "goals," "grow," "guidance," "intend," "likely," "may," "milestone," "objective," "on track," "opportunity," "outlook," "pending," "plan," "poised," "position," "possible," "potential," "predict," "progress," "promises," "roadmap," "seek," "should," "strive," "targets," "to be," "upcoming," "will," "would," and variations of such words and similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. Factors that may cause actual results to differ materially include, but are not limited to, the following: the availability of cash on hand; potential material delays in realizing projected timelines for Sonim's products; the current interest and potential attempt of a hostile takeover from a third party may divert the management attention from Sonim's business and may require significant expenses; Sonim's susceptibility to supply chain disruptions; a potential strain on Sonim's resources as a result of rapid customer ramp-up and significant increases in demand; Sonim's material dependence on its relationship with a small number of customers who account for a significant portion of Sonim's revenue; risks related to Sonim's ability to comply with the continued listing standards of the Nasdaq Stock Market and the potential delisting of Sonim's common stock; Sonim's ability to continue to develop solutions to address user needs effectively, including its next-generation products; Sonim's reliance on third-party contract manufacturers and partners; Sonim's ability to stay ahead of the competition; Sonim's ongoing transformation of its business; the variation of Sonim's quarterly results; the lengthy customization and certification processes for Sonim's wireless carries customers; various economic, political, environmental, social, and market events beyond Sonim's control, as well as the other risk factors described under "Risk Factors" included in Sonim's most recent Annual Report on Form 10-K and any subsequent quarterly filings on Form 10-Q filed with the Securities and Exchange Commission (available at Sonim cautions you not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Sonim assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Draup Launches Curie: The Agentic AI Built for Enterprise HR Teams
Draup Launches Curie: The Agentic AI Built for Enterprise HR Teams

Yahoo

time4 minutes ago

  • Yahoo

Draup Launches Curie: The Agentic AI Built for Enterprise HR Teams

THE WOODLANDS, Texas, July 16, 2025 /CNW/ -- Draup, the leader in enterprise talent intelligence, today announced the launch of Curie: a purpose-built agentic AI product that radically redefines how HR leaders turn complex labor and market data into strategic decisions. As enterprises navigate global talent shortages, rapid skill evolution, and rising pressure to future-proof their workforce, Curie steps in to close the gap between data overload and actionable talent decisions. "Curie is a GenAI Assistant purpose-built to combine Draup's powerful labor market data with the simplicity of natural conversation. From workforce planning and talent acquisition to skills architecture, Curie delivers instant, actionable insights that previously took weeks to generate. As a strategic digital twin, Curie empowers HR to shape the future of work with unprecedented speed and clarity. One of the most rewarding moments was when a senior HR leader shared that they used Curie to create a comprehensive white paper on location strategy for their CHRO—in under two hours." — Vijay Swaminathan, CEO & Co-Founder, Draup Built on one of the world's richest labor and market datasets spanning 1.5 million companies, 18,000 skills, 850 million professionals, and 4 million career paths, Curie makes workforce planning radically faster, smarter, and easier. Talent teams can use Curie to explore emerging skills across domains like AI and cybersecurity, assess the best global locations to hire specific talent, and identify redundant roles. They can also evaluate reskilling paths for impacted employees, compare compensation benchmarks across geographies, and understand how to evolve their talent architecture to align with business transformation. A New Kind of AI for HR: Agentic, Not Just Assistive Unlike conventional AI assistants, Curie is agentic. It is designed to take initiative, understand context, and navigate vast, interconnected data to deliver decision-ready insights. "Most business and HR leaders recognize the critical role of workforce planning in enabling business performance. Yet, organizations often struggle to execute it effectively. Curie by Draup is one of the most promising solutions for closing this gap — unlocking the power of agentic AI and labor market data for faster, more informed talent decisions that drive business results." — Brian Heger, Founder of Talent Edge Weekly Curie allows users to: Uncover skill gaps, forecast demand, and align workforce transformation Identify emerging roles, design reskilling paths, and stay ahead of talent shifts Benchmark compensation trends, identify strategic whitespace, and model location strategies And more Ready to Meet Curie: Book a demo to experience how Draup's agentic AI can reshape the way enterprises make decisions. About Draup Draup is a Talent Strategy Platform that equips HR leaders with real-time labor and market data to power workforce planning, recruitment, and skills transformation. By offering deep insights into global talent, peer benchmarks, and career pathing, Draup helps organizations design future-ready workforce strategies with precision and confidence. For media inquiries, please contact: Shyam RavishankarHead of Marketing Logo: View original content: SOURCE Draup View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034
Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034

Yahoo

time4 minutes ago

  • Yahoo

Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034

The global preclinical CRO market size is calculated at USD 6.80 billion in 2025 and is expected to reach around USD 14.34 billion by 2034, growing at a CAGR of 8.73% for the forecasted period. Ottawa, July 16, 2025 (GLOBE NEWSWIRE) -- The global preclinical CRO market size was valued at USD 6.25 billion in 2024 and is predicted to hit around USD 14.34 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research. Get a quick preview of key insights and trends shaping the preclinical CRO market: The growth of the market is driven by the major pharmaceutical companies and increased research and development in the developing regions, furthering the growth of the market. Key Takeaways North America led the global market with the highest market share of 48% in 2024. Asia Pacific is expected to grow at the fastest CAGR over the forecast period, 2025 to 2034. By service, the toxicology testing segment accounted for the largest revenue share in the global preclinical CRO market in 2024. By service, the bioanalysis and DMPK studies segment is anticipated to grow at the fastest rate during the forecast period. By model type, the patient-derived organoid (PDO) model segment held the largest share in 2024. By model type, the patient-derived xenografts (PDXs) model segment is expected to expand at a significant CAGR throughout the forecast period. By end use, the biopharmaceutical companies segment held the largest shares in 2024. By end-use, the government and academic institutes segment is expected to register the fastest growth during the forecast period. Preclinical CRO Market Overview & Potential A preclinical CRO (Contract Research Organization) offers vital research services mainly during the early, preclinical stage of developing drugs and medical devices, before human trials start. These organizations perform studies, including lab and animal testing, to assess the safety, effectiveness, and pharmacological characteristics of new treatments or devices. This critical phase gathers necessary data for regulatory filings such as Investigational New Drug (IND) applications and ensures safety before human testing. Preclinical CROs are essential in the initial development phases by delivering testing, data collection, and regulatory assistance, thereby supporting the progress of new therapies and medical innovations. Access detailed market data, segment breakdowns, and growth projections in one place: What Are the Key Growth Factors Responsible for The Growth of The Preclinical CRO Market? The key growth drivers responsible for the growth of the market are the increased complexity and cost of drug development, rising prevalence of chronic diseases, regulatory stringency, and advanced technological advancements are the key growth drivers which help in the growth of the market. The growth of the biotechnology sector, with its focus on biologics, cell and gene therapies, and other advanced therapies, is in increasing demand. The increased research and development by the pharmaceutical and biotechnology companies further boost the growth of the market, supporting the expansion. What Are the Growing Trends Associated with The Preclinical CRO Market? Advancements in Technology The technological advancements, like the integration of AI, high-throughput screening, and in vivo imaging to enable more efficient and personalized research, are a growing trend. Increased Outsourcing Increasing outsourcing by pharmaceutical and biotech companies to leverage specialized expertise, reduce costs, and accelerate drug development fuels the growth. Focus on Specialized Services The growing demand for specialized services like personalized medicines and biologics, and testing procedures further drives the growth of the market. Growing Demand for CROs The growing demand to enhance and improve efficiency for substantial growth in the market and testing boosts the demand. What Is the Growing Challenge in The Preclinical CRO Market? The key challenge that limits the growth of the market is the regulatory hurdles, like complex compliance, time-consuming approvals, data integrity maintaining high data quality in large-scale research is a challenge which hinders the growth of the market. The cost and complexity of maintaining quality and reliability are a major challenge that hinders the growth of the market. You can place an order or ask any questions, please feel free to contact us at sales@ Regional Analysis How Did North America Dominate the Preclinical CRO Market In 2024? North America led the global market with the highest market share of 48% in 2024. The growth of the market is driven by the increasing research and development investments, the rising prevalence of chronic diseases, and the presence of large major pharmaceutical and biotechnology companies, which fuel the growth of the market in the region. The well-established healthcare infrastructure and strong presence of major companies like Charles River Laboratories, LabCorp Drug Development, and Eurofins Scientific further fuel the growth of the market. The growth of the market is also driven by increased cost reduction and the ongoing development in therapeutic areas like gene therapy and neurodegenerative diseases, further fueling the growth of the market and supporting its expansion of the market. Preclinical CROs in the U.S. are expanding rapidly due to rising demand for faster, cost-effective drug development. These organizations offer specialized services in toxicology, pharmacology, and bioanalysis, helping streamline R&D pipelines. Technological advancements and regulatory complexities are driving sponsors to outsource, fostering deeper collaborations and innovation within the life sciences sector. Canada's preclinical CRO sector is scaling rapidly, notably in Ontario and Quebec. Providers like BenchSci (AI-enabled target screening) and IonsGate (expanded toxicology services) enhance provincial R&D pipelines. Altasciences' Mississauga labs handle diverse in vivo models. Partnerships with Health Canada and CIHR grants support facility expansion and deeper pharma-CRO cooperation. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: What Made Asia Pacific Significantly Grow in The Preclinical CRO Market In 2024? Asia Pacific is expected to grow at the fastest CAGR over the forecast period, 2025 to 2034. The growth of the market is driven by the offering of cost-effectiveness of research and development and the offering of effective solutions for preclinical research, which attracts national and international pharmaceutical companies for investments, which increases the growth of the market in the region. The growth is also driven by the expanding biopharma companies, and expanding research also demands and needs preclinical CRO services. Additionally, advancements in personalized medicines and oncology research in the region, with government support and infrastructure due to an increase in clinical trials, drive significant growth and expansion of the market in the region. Chinese preclinical CROs led by giants like WuXi AppTec and Pharmaron have built globally compliant GLP labs in Suzhou, Shanghai, and Wuhan. They now offer advanced in vivo ADME/Tox, NHP models, isotope-based DMPK, and continuous-infusion rodent studies. High-tech-park clusters and regulatory accreditation drive international-grade services. India's preclinical CRO landscape is expanding in Hyderabad, Bengaluru, and Pune. Providers like GVK Bio and Jubilant Biosys operate GLP-certified toxicology and pharmacology labs. Emerging capabilities include canine and NHP models, PK/PD biomarker development, whole-body autoradiography, and AI-assisted data analytics. Collaborations with DST and DBT bolster translational study infrastructure. Segmental Insights By service How Did Service Segment Dominate the Preclinical CRO Market In 2024? The toxicology testing segment accounted for the largest revenue share in the global market in 2024. Toxicology testing services in the market play a vital role in assessing the safety profile of new drug candidates before they enter clinical trials. These services help identify potential toxic effects on different organs and systems, ensuring regulatory compliance and minimizing risks to human health. With increasing drug development activities and stringent safety regulations, demand for reliable toxicology testing is growing rapidly. This supports the expansion of preclinical CRO services, enabling pharmaceutical and biotech companies to advance their pipelines efficiently and safely. The bioanalysis and DMPK studies segment is anticipated to grow at the fastest rate during the forecast period. Bioanalysis and DMPK (Drug Metabolism and Pharmacokinetics) studies are essential services offered by preclinical CROs to evaluate the absorption, distribution, metabolism, and excretion of drug candidates. These studies provide crucial data on drug behaviour in the body, guiding dose selection and safety assessments before clinical trials. The growing need for precise pharmacokinetic data to meet regulatory requirements and optimize drug design fuels the demand for these services, supporting market growth and accelerating drug development timelines for pharmaceutical companies. By model type Which Patient-Derived Organoid Model Segment Dominated the Preclinical CRO Market In 2024? The patient-derived organoid (PDO) model segment held the largest share in 2024. Patient-derived organoid models in the preclinical CRO market are gaining significant attention due to their ability to closely mimic human tissue and tumor microenvironments. These 3D models, developed from patient-specific cells, enable more accurate prediction of drug responses and toxicity compared to traditional models. They support personalized medicine approaches and improve the success rate of drug candidates by providing better translational relevance. The increasing demand for more precise and human-relevant models drives the adoption of patient-derived organoids, fueling market growth. The patient-derived xenografts (PDXs) model segment is expected to expand at a significant CAGR throughout the forecast period. Patient-derived xenograft (PDX) models are increasingly used in the preclinical CRO market due to their high predictive value for human clinical outcomes. In these models, tumor tissues from patients are implanted into immunodeficient mice, preserving the original tumor's characteristics and heterogeneity. PDX models enable researchers to study tumor behavior, evaluate drug efficacy, and identify potential biomarkers more accurately. The rising focus on personalized medicine and the need for clinically relevant data drive demand for PDX models, supporting market expansion. By end use Which End Use Segment Dominated the Preclinical CRO Market In 2024? The biopharmaceutical companies segment held the largest shares in 2024. Biopharmaceutical companies are major end users in the preclinical CRO market, relying heavily on these services to accelerate and streamline their drug development pipelines. By outsourcing preclinical studies such as toxicology, bioanalysis, DMPK, and efficacy testing, these companies reduce costs, minimize risks, and access specialized expertise and advanced models. This enables them to focus on core research activities and bring innovative therapies to market faster. The growing emphasis on biologics and complex molecules further fuels demand, driving market growth and expansion. The government and academic institutes segment is expected to register the fastest growth during the forecast period. Government and academic institutes play a crucial role as end users in the preclinical CRO market, utilizing outsourced research services to advance scientific knowledge and support public health initiatives. These institutions often engage CROs for specialized studies, including safety evaluations, mechanistic research, and early-stage drug discovery, due to limited in-house resources or expertise. Their focus on translational research, new therapeutic approaches, and regulatory science drives the demand for high-quality preclinical services, supporting market growth and healthcare innovation. Get the latest insights on life science industry segmentation with our Annual Membership: Recent Developments In April 2025, Debiopharm Research & Manufacturing S.A., a Swiss-based global biopharmaceutical company, launched a license agreement for the use of the AbYlink™ technology for preclinical services. In November 2024, Thermo Fisher Scientific launched a suite of expanded CRO and CDMO services under its brand. The company has introduced to the market its Accelerator™ Drug Development, which Thermo Fisher is marketing as '360°' CDMO and CRO drug development solutions. Top Companies and Their Contributions to the Preclinical CRO Market Company Key Contributions and Offerings WuXi AppTec Offers end-to-end preclinical services in toxicology, pharmacology, and DMPK; strong in IND-enabling studies and global regulatory compliance. Pharmaceutical Product Development (PPD) Specializes in nonclinical safety studies, ADME, and bioanalytical services; strong support for early-phase compound selection and optimization. Medpace, Inc. Provides integrated preclinical trial design and execution; strengths in pharmacokinetics, toxicology, and disease models, particularly in oncology and cardiology. Charles River Laboratories Industry leader in in vivo and in vitro safety assessments, genetic toxicology, and pathology; offers extensive animal model capabilities. PRA Health Sciences Known for translational medicine and biomarker development, it combines lab and clinical data to enhance candidate evaluation. PAREXEL Delivers regulatory consulting, toxicology, and pathology services; known for integrating preclinical findings into clinical strategy. Envigo Offers regulatory toxicology, safety pharmacology, and metabolism studies; robust capabilities in GLP and non-GLP environments. Eurofins Scientific Provides comprehensive testing services including genotoxicity, ecotoxicology, and bioanalytics; also specializes in agrochemical safety. LabCorp (Covance) Delivers large-scale preclinical services in drug metabolism, bioanalytical chemistry, and regulatory toxicology. ICON Plc Offers early-phase lab services including preclinical feasibility studies, assay development, and integrated biomarker strategies. Browse More Insights of Towards Healthcare: The global medical device CRO market was valued at USD 8.49 billion in 2024 and increased to USD 9.25 billion in 2025. It is expected to reach USD 19.9 billion by 2034, growing steadily at a CAGR of 8.98% from 2025 to 2034. The biopharmaceuticals CRO market is showing strong growth and is expected to generate significant revenue, reaching hundreds of millions of dollars between 2025 and 2034. The global healthcare CRO market was valued at USD 53.87 billion in 2024, grew to USD 57.66 billion in 2025, and is projected to reach USD 106.25 billion by 2034, growing at a CAGR of 7.04% over the forecast period. The pharma CRO services market is expected to grow from USD 36.66 billion in 2025 to USD 87.03 billion by 2034, with a healthy CAGR of 10.04% from 2025 to 2034. The preclinical advanced cell models market is also expanding rapidly and is forecasted to earn hundreds of millions in revenue between 2025 and 2034. The global mRNA therapeutics CDMO market grew from USD 4.62 billion in 2024 to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37%. The drug discovery as a service market was worth USD 21.3 billion in 2024, rose to USD 24.32 billion in 2025, and is expected to reach USD 79.82 billion by 2034, growing at a robust CAGR of 14.17%. The CDMO services market for pharma and biotech is experiencing significant growth between 2024 and 2034, driven by a strong shift toward outsourcing by these industries. The global cell culture media market increased from USD 6.9 billion in 2024 to USD 7.69 billion in 2025, and is projected to reach USD 20.32 billion by 2034, growing at a CAGR of 11.45%. The small molecule CDMO market was valued at USD 72.81 billion in 2024, reached USD 78.01 billion in 2025, and is forecasted to hit USD 145.12 billion by 2034, growing at a CAGR of 7.14%. Key Players List of Preclinical CRO Market Wuxi AppTec Pharmaceutical Product Development Medpace, Inc. Charles River Laboratories International, Inc. PRA Health Science, Inc. PAREXEL Envigo Eurofins Scientific Laboratory Corporation of America ICON Plc Intertek Group Plc (IGP) LABCORP Crown Bioscience PPD (Thermo Fisher Scientific, Inc.) Segments Covered in the Report By Service Bioanalysis and DMPK studies In vitro ADME In vivo PK Toxicology Testing GLP Non-GLP Compound Management Process R&D Custom Synthesis Others Chemistry Medicinal Chemistry Computational Chemistry Safety Pharmacology Others By Model Type Patient-Derived Organoid (PDO) Model Patient-derived xenograft model By End-use Biopharmaceutical Companies Government and Academic Institutes Medical Device Companies By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Unlock the complete preclinical CRO market analysis, with strategic insights and expert forecasts: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire For Latest Update Follow Us: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store